21 November
Pure Biologics submits an eIND application to the FDA for the start of Phase 0 in the PB004 project and decides on the further development of PB003G toward Phase 0.
Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.

Pure Biologics - Harnessing the power of antibodies and aptamers